Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BCYC Stock Summary
Top 10 Correlated ETFs
BCYC
In the News
2 More Potential Biotech Buyout Targets
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego on April 5-10. Poster Presentation Details: Title: Bicycle Toxin Conjugates® for the.
Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up
Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to support its accelerated approval. The stock rises 9%.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Shares of Bicycle Therapeutics Were Rising on Monday
Bicycle Therapeutics has 14 programs in its pipeline. The company is a clinical-stage biotech.
Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023, at 10:10 a.m. ET. A live webcast of the fireside chat will be accessible in the Investors & Media s.
Bicycle Therapeutics: Decent Upside Opportunity, Mid-Stage Data Readouts Due
Bicycle Therapeutics is an intriguing play in the drug development space. Using its fully synthetic short peptides, the company has developed two mid-stage oncology assets that have achieved some results of interest in urothelial / ovarian cancers. The company also has numerous potentially lucrative co-development opportunities with the likes of Roche, Novartis, Ionis Pharmaceuticals.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Bicycle Therapeutics Stock Raced Ahead Today
The U.K.-based biotech announced a fresh offering of its ADSes. It's seeking to net around $187 million in proceeds with the issue.
Bicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs Yet
BCYC's distinction is that it is founded by a Nobel laureate. However, unless it can differentiate its product's efficacy from that of mAbs, that may be its only distinction.
BCYC Financial details
BCYC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.25 | 0.54 | 0.47 | 0.49 | 0.76 | |
Net income per share | -2.77 | -2.66 | -2.67 | -3.8 | -5.08 | |
Operating cash flow per share | -2.59 | -0.93 | -0.59 | -2.9 | -1.7 | |
Free cash flow per share | -2.73 | -0.99 | -0.67 | -3.54 | -1.79 | |
Cash per share | 8.34 | 7.1 | 17.5 | 11.43 | 14.79 | |
Book value per share | 8.44 | 4.99 | 13.82 | 9.13 | 10.42 | |
Tangible book value per share | 8.44 | 4.99 | 13.82 | 9.13 | 10.42 | |
Share holders equity per share | 8.44 | 4.99 | 13.82 | 9.13 | 10.42 | |
Interest debt per share | 0.17 | 0.85 | 1.89 | 1.61 | 1.35 | |
Market cap | 104.16M | 343.67M | 1.53B | 877.96M | 643.51M | |
Enterprise value | 13.93M | 223.45M | 1.13B | 583.13M | 162.04M | |
P/E ratio | -3.4 | -6.74 | -22.83 | -7.79 | -3.56 | |
Price to sales ratio | 7.55 | 33.08 | 130.42 | 60.7 | 23.85 | |
POCF ratio | -3.64 | -19.32 | -103.12 | -10.2 | -10.61 | |
PFCF ratio | -3.45 | -18.1 | -90.67 | -8.35 | -10.12 | |
P/B Ratio | 1.12 | 3.6 | 4.41 | 3.24 | 1.73 | |
PTB ratio | 1.12 | 3.6 | 4.41 | 3.24 | 1.73 | |
EV to sales | 1.01 | 21.51 | 96.71 | 40.32 | 6.01 | |
Enterprise value over EBITDA | -0.53 | -4.36 | -17.27 | -5.26 | -0.96 | |
EV to operating cash flow | -0.49 | -12.56 | -76.46 | -6.77 | -2.67 | |
EV to free cash flow | -0.46 | -11.77 | -67.24 | -5.55 | -2.55 | |
Earnings yield | -0.29 | -0.15 | -0.04 | -0.13 | -0.28 | |
Free cash flow yield | -0.29 | -0.06 | -0.01 | -0.12 | -0.1 | |
Debt to equity | 0.02 | 0.17 | 0.13 | 0.16 | 0.12 | |
Debt to assets | 0.02 | 0.1 | 0.09 | 0.11 | 0.08 | |
Net debt to EBITDA | 3.43 | 2.34 | 6.02 | 2.66 | 2.85 | |
Current ratio | 11.81 | 6.73 | 12.65 | 6.92 | 8.08 | |
Interest coverage | 0 | -113.7 | -21.99 | -34.88 | -58.21 | |
Income quality | 0.93 | 0.35 | 0.22 | 0.76 | 0.34 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.05 | 2.81 | 2.77 | 3.42 | 2.22 | |
Research and developement to revenue | 1.85 | 3.19 | 3.84 | 5.64 | 5.8 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.05 | 0.07 | 0.14 | 0.22 | 0.05 | |
Capex to revenue | -0.11 | -0.12 | -0.17 | -1.31 | -0.11 | |
Capex to depreciation | -1.62 | -0.94 | -1.44 | -5.15 | -0.45 | |
Stock based compensation to revenue | 0.22 | 0.63 | 1.03 | 1.85 | 1.2 | |
Graham number | 22.94 | 17.29 | 28.79 | 27.94 | 34.5 | |
ROIC | -0.27 | -0.46 | -0.16 | -0.35 | -0.45 | |
Return on tangible assets | -0.28 | -0.32 | -0.14 | -0.27 | -0.3 | |
Graham Net | 7.29 | 4.24 | 12.53 | 7.26 | 8.99 | |
Working capital | 95.33M | 132.59M | 422.32M | 316.04M | 492.33M | |
Tangible asset value | 93.2M | 95.46M | 346.25M | 270.78M | 370.93M | |
Net current asset value | 87.15M | 90.03M | 325.02M | 229.56M | 337.46M | |
Invested capital | 0.02 | 0.17 | 0.13 | 0.16 | 0.12 | |
Average receivables | 9.23M | 10.89M | 13.27M | 16.56M | 22.62M | |
Average payables | 1.92M | 1.66M | 2.04M | 4.6M | 9.76M | |
Average inventory | 0.5 | 0.5 | 0 | 0.5 | 0.5 | |
Days sales outstanding | 188.97 | 514.06 | 371.65 | 535.2 | 325.26 | |
Days payables outstanding | 27.85 | 15.03 | 22.13 | 640.75 | 724.85 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.93 | 0.71 | 0.98 | 0.68 | 1.12 | |
Payables turnover | 13.1 | 24.28 | 16.49 | 0.57 | 0.5 | |
Inventory turnover | 25.54M | 0 | 0 | 3.69M | 0 | |
ROE | -0.33 | -0.53 | -0.19 | -0.42 | -0.49 | |
Capex per share | -0.14 | -0.06 | -0.08 | -0.64 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.11 | 0.16 | 0.38 | 0.14 | 0.13 | |
Net income per share | -1.01 | -1.3 | -1.41 | -1.26 | -1.16 | |
Operating cash flow per share | -1.02 | -1.55 | 1.13 | -0.03 | -1.11 | |
Free cash flow per share | -1.07 | -1.62 | 1.12 | -0.04 | -1.12 | |
Cash per share | 11.41 | 9.79 | 11.28 | 14.46 | 12.41 | |
Book value per share | 9.11 | 8.1 | 7.29 | 10.51 | 8.74 | |
Tangible book value per share | 9.11 | 8.1 | 7.29 | 10.51 | 8.74 | |
Share holders equity per share | 9.11 | 8.1 | 7.29 | 10.51 | 8.74 | |
Interest debt per share | 1.52 | 1.68 | 1.59 | 1.17 | 1.08 | |
Market cap | 879.46M | 638.14M | 770.49M | 795.09M | 766.94M | |
Enterprise value | 584.63M | 393.79M | 477.13M | 268.69M | 285.47M | |
P/E ratio | -7.33 | -4.08 | -4.52 | -3.98 | -3.91 | |
Price to sales ratio | 276.13 | 130.34 | 67.6 | 148.56 | 143.86 | |
POCF ratio | -29.02 | -13.75 | 22.6 | -775.7 | -16.22 | |
PFCF ratio | -27.69 | -13.15 | 22.78 | -520.69 | -16.2 | |
P/B Ratio | 3.25 | 2.62 | 3.5 | 1.91 | 2.07 | |
PTB ratio | 3.25 | 2.62 | 3.5 | 1.91 | 2.07 | |
EV to sales | 183.56 | 80.43 | 41.86 | 50.2 | 53.55 | |
Enterprise value over EBITDA | -19.77 | -10.13 | -11.62 | -6.05 | -6.14 | |
EV to operating cash flow | -19.29 | -8.48 | 13.99 | -262.14 | -6.04 | |
EV to free cash flow | -18.41 | -8.12 | 14.11 | -175.96 | -6.03 | |
Earnings yield | -0.03 | -0.06 | -0.06 | -0.06 | -0.06 | |
Free cash flow yield | -0.04 | -0.08 | 0.04 | 0 | -0.06 | |
Debt to equity | 0.16 | 0.2 | 0.21 | 0.11 | 0.12 | |
Debt to assets | 0.11 | 0.12 | 0.1 | 0.07 | 0.08 | |
Net debt to EBITDA | 9.97 | 6.29 | 7.15 | 11.85 | 10.36 | |
Current ratio | 6.92 | 7.19 | 5.65 | 8.65 | 8.08 | |
Interest coverage | -39 | -51.74 | -52.51 | -62.4 | -66.14 | |
Income quality | 1.01 | 1.19 | -0.8 | 0.02 | 0.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.35 | 2.96 | 1.33 | 2.91 | 2.82 | |
Research and developement to revenue | 7.76 | 6.58 | 3.49 | 7.45 | 8.38 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.05 | 0.05 | -0.01 | 0.49 | 0 | |
Capex to revenue | -0.45 | -0.43 | -0.02 | -0.09 | -0.01 | |
Capex to depreciation | -1.04 | -1.35 | -0.17 | -0.3 | -0.03 | |
Stock based compensation to revenue | 1.74 | 1.85 | 0.72 | 1.39 | 1.47 | |
Graham number | 14.38 | 15.41 | 15.21 | 17.27 | 15.09 | |
ROIC | -0.1 | -0.13 | -0.15 | -0.11 | -0.13 | |
Return on tangible assets | -0.07 | -0.09 | -0.09 | -0.08 | -0.08 | |
Graham Net | 7.24 | 5.52 | 4.96 | 9.16 | 7.54 | |
Working capital | 316.04M | 328.26M | 336.16M | 533.3M | 492.33M | |
Tangible asset value | 270.78M | 243.16M | 220.1M | 416.02M | 370.93M | |
Net current asset value | 229.56M | 195.62M | 174.36M | 380.38M | 337.46M | |
Invested capital | 0.16 | 0.2 | 0.21 | 0.11 | 0.12 | |
Average receivables | 16.29M | 48.86M | 67.24M | 37.63M | 20.66M | |
Average payables | 6.76M | 4.64M | 4.03M | 6.87M | 10.77M | |
Average inventory | 0.5 | 1 | 0.5 | 0 | 0 | |
Days sales outstanding | 599.26 | 1.41K | 457.81 | 290.53 | 405.84 | |
Days payables outstanding | 417.13 | 161.14 | 286.31 | 454.93 | 703.97 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.15 | 0.06 | 0.2 | 0.31 | 0.22 | |
Payables turnover | 0.22 | 0.56 | 0.31 | 0.2 | 0.13 | |
Inventory turnover | 1.4M | 1.57M | 0 | 0 | 0 | |
ROE | -0.11 | -0.16 | -0.19 | -0.12 | -0.13 | |
Capex per share | -0.05 | -0.07 | -0.01 | -0.01 | 0 |
BCYC Frequently Asked Questions
What is Bicycle Therapeutics plc stock symbol ?
Bicycle Therapeutics plc is a GB stock and trading under the symbol BCYC
Is Bicycle Therapeutics plc buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $70.5. The lowest prediction is $65 and the highest is $76
What is BCYC stock prediction ?
What is Bicycle Therapeutics plc stock quote today ?
Bicycle Therapeutics plc stock price is $24.9 today.
Is Bicycle Therapeutics plc stock public?
Yes, Bicycle Therapeutics plc is a publicly traded company.